Tozuleristide荧光标记在乳腺标本中实时可视化癌组织
结果显示荧光可见于浸润性和原位癌,浸润癌多呈明亮局灶性,原位病变信号较弱且弥漫,分子标志物状态不影响信号,荧光有助于术中判断肿瘤与切缘关系。
要点
- Tozuleristide荧光可实时区分病理证实的乳腺癌与正常组织。
- 浸润癌荧光多明亮局灶,原位癌信号较弱且弥漫。
- 分子标志物/激素受体状态不影响荧光信号。
核心结论
- Tozuleristide靶向肿瘤可实现病理证实的乳腺癌与正常组织的视觉实时区分。
研究设计与样本
- 由临床病理人员使用研究性近红外成像设备SIRIS行离体荧光成像,随后按常规流程处理并与HE切片对照。
主要发现
- Tozuleristide荧光在浸润性和原位乳腺癌标本中易于观察到。
- 多数浸润癌呈明亮且局灶的荧光,原位病变呈强度较低且更弥漫的模式。
- 导管癌和小叶癌的荧光模式相似,高、低级别病变均可检测到荧光。
- 分子标志物/激素受体状态不影响荧光信号。
- 荧光可用于术中识别癌与切缘的关系。
临床怎么用
- 该研究性荧光剂有望辅助新鲜乳腺病理标本的实时癌灶识别和术中切缘评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: Resection of breast carcinoma with adequate margins reduces the risk of local recurrence and reoperation. Tozuleristide (BLZ-100) is an investigational peptide-fluorophore agent that may aid in intraoperative tumor detection and margin assessment. In this study, fluorescence imaging was conducted ex vivo on gross breast pathology specimens. OBJECTIVES.—: To determine the potential of tozuleristide to detect breast carcinoma in fresh pathology specimens and the feasibility of fluorescence-guided intraoperative pathology assessment of surgical margins. DESIGN.—: Twenty-three patients received an intravenous bolus dose of 6 or 12 mg of tozuleristide at least 1 hour before surgery. Fifteen lumpectomy and 12 mastectomy specimens were evaluated for fluorescence by the site's clinical pathology staff using the SIRIS, an investigational near-infrared imaging device. The breast tissue was then processed per usual procedures. Fluorescent patterns were correlated with the corresponding hematoxylin-eosin-stained sections. Clinical pathology reports were used to correlate fluorescent signal to grade, histotype, prognostic marker status, and margin measurements. RESULTS.—: Tozuleristide fluorescence was readily observed in invasive and in situ breast carcinoma specimens. Most invasive carcinomas were bright and focal, whereas in situ lesions demonstrated a less intense, more diffuse pattern. Tozuleristide was detected in ductal and lobular carcinomas with a similar fluorescent pattern. Fluorescence was detected in high- and low-grade lesions, and molecular marker/hormone receptor status did not affect signal. Fluorescence could be used to identify the relationship of carcinoma to margins intraoperatively. CONCLUSIONS.—: Tumor targeting with tozuleristide allowed visual real-time distinction between pathologically confirmed breast carcinoma and normal tissue.
引用
- Dintzis SM, Hansen S, Harrington KM, et al. Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide. Arch Pathol Lab Med. 2018. PMID: 30550350. doi:10.5858/arpa.2018-0197-OA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。